Summary of PTC Therapeutics PKU Deep Dive Conference Call Company Overview - PTC Therapeutics is a global biopharmaceutical company focused on innovative therapies for rare disorders, with a robust commercial portfolio of six marketed products, five of which are global, and one generating collaboration and royalty revenue [5][6] - The company aims to achieve total revenue guidance of $940 million to $1 billion for 2023, including $545 million to $565 million from DMD revenue [6] Product Focus: Sepiaterin for PKU - The primary focus of the call is on sepiaterin, a treatment for phenylketonuria (PKU) [8] - The Phase 3 APHINITY trial showed a 63% reduction in blood phenylalanine levels in the overall primary analysis population and 69% in classical PKU patients, with a p-value of less than 0.0001, indicating statistical significance [9][10] - 84% of patients achieved target phenylalanine levels below 360 micromoles per liter, and 93% of adolescents and adults achieved levels below 600 micromoles per liter [10] - Sepiaterin was well tolerated with no serious adverse events reported [9] Clinical Insights - PKU is caused by variants in the PAH gene, leading to impaired PAH function and elevated phenylalanine levels, which can have neurological consequences [17][19] - Current treatments, Kuvan and Palynziq, have limitations, including low response rates and safety concerns, highlighting the need for new therapies like sepiaterin [30][32][39] - Sepiaterin offers mechanistic advantages, including better absorption and bioavailability compared to existing treatments, and has shown potential to treat a broader patient population, including those with classical PKU [35][39] Unmet Needs and Market Opportunity - Less than 10% of diagnosed PKU patients are well-controlled on Kuvan, with around 70% of patients trialed on Kuvan not responding adequately [41] - The patient journey begins with newborn screening, and the need for lifelong dietary restrictions significantly impacts quality of life, leading to social isolation and mental health issues [42][43][44] - The potential market opportunity for sepiaterin is estimated to be between $1 billion and $1.5 billion, targeting 15% to 30% of the global PKU population [62][73] Commercial Strategy - PTC Therapeutics has established relationships with key opinion leaders and treatment centers, positioning itself for a successful launch of sepiaterin [63][68] - The company plans to differentiate sepiaterin through its data package, mechanistic advantages, and support for the PKU community [72] - The launch strategy includes targeting therapy-naive patients, those who have failed Kuvan, and patients inadequately controlled on existing therapies [61][70] Conclusion - Sepiaterin represents a significant advancement in the treatment of PKU, with strong clinical data supporting its efficacy and safety [39][60] - The company is preparing for regulatory submissions and anticipates a successful commercial launch, aiming to address the substantial unmet needs in the PKU patient population [73]

Summary of PTC Therapeutics (PTCT) Update / Briefing May 23, 2023 Company Overview - **Company**: PTC Therapeutics (PTCT) - **Focus**: Development of therapies for rare diseases, specifically targeting Friedreich ataxia (FA) with the drug vutiquinone Key Points from the Call Study Results - **MoveFA Study**: A 72-week placebo-controlled trial of vutiquinone for Friedreich ataxia patients aged 7 to 21 years [3][4] - **Primary Endpoint**: Change in total modified Friedreich ataxia rating scale (mFARS) score from baseline to week 72; did not achieve statistical significance [7][12] - **Secondary Endpoints**: Notable treatment benefits observed in bulbar function and upright stability subscales with nominal p-values of 0.044 and 0.021 respectively [7][12] - **Fatigue Scale**: Significant improvement noted, as fatigue is a major symptom for FA patients [8][12] - **Completer Analysis**: Showed a 2.31 placebo-corrected difference in mFARS score, indicating a 75% slowing of disease progression over 72 weeks [9][10] Safety Profile - **Adverse Events**: Similar profiles between vutiquinone and placebo groups; common events included falls and gastrointestinal symptoms [11][12] - **Serious Events**: One death in each group, with the vutiquinone-related death attributed to cardiac failure [12] Regulatory and Strategic Decisions - **FDA and EMA Discussions**: Plans to share study results with regulatory agencies to explore potential approval pathways for pediatric FA patients [13] - **Portfolio Prioritization**: Decision to discontinue preclinical gene therapy programs and suspend development for certain gene therapy programs, resulting in a 15% reduction in operational expenses for 2023 [13][45] Financial Outlook - **Revenue Guidance**: No changes to revenue expectations; projected revenue remains between $940 million to $1 billion [41][45] - **Operational Expenses**: Focus on reducing OpEx while maintaining investment in promising R&D programs [75][78] Future Directions - **Open Label Extension Study**: Plans to analyze long-term effects beyond the 72-week study period [28][92] - **Subgroup Analysis**: Noted a larger treatment effect in younger patients (aged 16 and below) with a 2.38 improvement in mFARS score [94] Additional Insights - **Natural History Data**: The study's findings align with existing natural history data, reinforcing the drug's potential to modify disease progression [30][92] - **Regulatory Flexibility**: The company aims to leverage insights from other recent FDA approvals in rare diseases to support their case for vutiquinone [80][81] Conclusion - PTC Therapeutics is navigating a complex landscape in rare disease drug development, with promising data from the MoveFA study despite not meeting the primary endpoint. The company is strategically refocusing its resources and engaging with regulatory bodies to explore potential pathways for approval, particularly for pediatric patients with Friedreich ataxia.

Summary of PTC Therapeutics (PTCT) Update / Briefing May 17, 2023 Company Overview - **Company**: PTC Therapeutics (PTCT) - **Product**: Sepiaterin - **Indication**: Treatment of Phenylketonuria (PKU) Key Points Industry and Product Development - **Phase III Trial**: The AFFINITY trial for sepiaterin in patients with fetal ketonuria has shown positive top-line results, meeting the primary endpoint of blood phenylalanine reduction [2][19] - **Efficacy Results**: - Overall mean blood phenylalanine reduction of **63%** in the primary analysis population [2][8] - In classical PKU patients, the mean reduction was **69%** [2][8] - **84%** of patients achieved the target phenylalanine level of less than **360 micromoles per liter** [10] - **93%** of adolescents and adults met the European guideline target of below **600 micromoles per liter** [10] Trial Design and Results - **Trial Structure**: The trial included a run-in phase where patients were treated with sepiaterin for two weeks before randomization [3][4] - **Patient Population**: - Total of **156 patients** screened, with **103 patients** showing a reduction of greater than **30%** in blood phenylalanine levels [4][6] - **98 patients** were randomized for the primary analysis [6] - **Safety Profile**: - No serious adverse events reported; common adverse events included headache and diarrhea, mostly grade one [12][13][78] - Similar rates of treatment-related adverse events between sepiaterin and placebo groups [13][78] Market Opportunity - **Commercial Potential**: - PKU represents a unique commercial opportunity with an estimated **58,000 patients** worldwide [17] - Despite two approved therapies, a large unmet need exists, particularly for therapy-naive patients and those poorly controlled on existing treatments [17][18] - **Regulatory Strategy**: Plans to request pre-submission meetings with regulatory authorities and move forward with NDA and MAA submissions [19] Competitive Landscape - **Comparison with Kuvan**: - In a subset of patients previously treated with Kuvan, sepiaterin showed a **48%** reduction in blood phenylalanine levels compared to their baseline on Kuvan [11][25] - The trial results validate the superior efficacy of sepiaterin over Kuvan, with a higher percentage of patients achieving significant benefits [25][26] Future Directions - **Long-term Studies**: Ongoing long-term open-label studies to assess safety and durability of sepiaterin treatment [14][19] - **Phe Tolerance Protocol**: Preliminary data show that patients can tolerate increased phenylalanine intake while maintaining low blood levels [16][104] Conclusion - The AFFINITY trial results position sepiaterin as a promising treatment for PKU, with strong efficacy and safety data supporting its potential to address significant unmet medical needs in the PKU patient population [19][121]